Pharmaceutical Japanese pharma major Eisai has decided to close its Andover, Massachusetts site and establish the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility focused on immuno-dementia based on human genetics, aimed at innovative drug discovery in the field of dementia, in Cambridge, Massachusetts, the USA. 14 June 2018